keyword
MENU ▼
Read by QxMD icon Read
search

Antipsychotic Weight Gain

keyword
https://www.readbyqxmd.com/read/29334686/fat-mass-and-obesity-related-gene-variants-rs9939609-and-rs7185735-are-associated-with-second-generation-antipsychotic-induced-weight-gain
#1
Charlotte Schröder, Fabian Czerwensky, Stefan Leucht, Werner Steimer
INTRODUCTION: Weight gain is a limiting and frequent adverse effect of second-generation antipsychotic therapy. Identifying genetic risk factors would significantly improve pharmacotherapy. METHODS: We focused on rs7185735 and rs9939609, 2 common single nucleotide polymorphisms of the fat mass and obesity-associated (FTO) gene reported to be associated with obesity. Three-hundred fifty Caucasian inpatients were included in a naturalistic study. RESULTS: After 4 weeks of treatment, we did not observe any significant association of polymorphisms with weight change in the whole study population (p>0...
January 15, 2018: Pharmacopsychiatry
https://www.readbyqxmd.com/read/29328360/metabolic-side-effects-in-patients-using-atypical-antipsychotic-medications-during-hospitalization
#2
Gül Dikeç, Leyla Baysan Arabaci, Gülçin Bölük Uzunoglu, Selin Demet Mizrak
The current research evaluated metabolic side effects in inpatients (N = 271) using atypical antipsychotic medications in a psychiatric hospital in Turkey between June and December 2016. Data were collected via an information form created after reviewing the literature at the time of patients' hospitalization and discharge. According to the analysis, 73.8% of patients stated they experienced side effects from antipsychotic medications and 20.7% of patients experienced weight gain. A statistical difference was detected among body mass index, waist circumference, diastolic blood pressure, and heart rate during patient hospitalization and discharge...
January 11, 2018: Journal of Psychosocial Nursing and Mental Health Services
https://www.readbyqxmd.com/read/29325867/atypical-antipsychotics-insulin-resistance-and-weight-a-meta-analysis-of-healthy-volunteer-studies
#3
Kyle J Burghardt, Berhane Seyoum, Abdullah Mallisho, Paul R Burghardt, Renu A Kowluru, Zhengping Yi
Atypical antipsychotics increase the risk of diabetes and cardiovascular disease through their side effects of insulin resistance and weight gain. The populations for which atypical antipsychotics are used carry a baseline risk of metabolic dysregulation prior to medication which has made it difficult to fully understand whether atypical antipsychotics cause insulin resistance and weight gain directly. The purpose of this work was to conduct a systematic review and meta-analysis of atypical antipsychotic trials in healthy volunteers to better understand their effects on insulin sensitivity and weight gain...
January 8, 2018: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/29324345/synthesis-and-biological-evaluation-of-a-series-of-multi-target-n-substituted-cyclic-imide-derivatives-with-potential-antipsychotic-effect
#4
Mingshuo Xu, Yu Wang, Feipu Yang, Chunhui Wu, Zhen Wang, Bin Ye, Xiangrui Jiang, Qingjie Zhao, Jianfeng Li, Yongjian Liu, Junchi Zhang, Guanghui Tian, Yang He, Jingshan Shen, Hualiang Jiang
In the present study, a series of multi-target N-substituted cyclic imide derivatives which possessed potent dopamine D2, serotonin 5-HT1A and 5-HT2A receptors properties were synthesized and evaluated as potential antipsychotics. Among these compounds, (3aR,4R,7S,7aS)-2-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butyl)-3a,4,7,7a-tetrahydro-1H-4,7-methanoisoindole-1,3(2H)-dione hydrochloride (3d) held a promising pharmacological profile. 3d not only showed potent and balanced in vitro activities on D2/5-HT1A/5-HT2A receptors, but also endowed with low to moderate activities on 5-HT2C, H1, α1A, M3 receptors and hERG channel, suggesting a low liability to induce side effects such as weight gain, orthostatic hypotension and QT prolongation...
January 4, 2018: European Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/29307079/functional-changes-of-orexinergic-reaction-to-psychoactive-substances
#5
REVIEW
Vincenzo Monda, Monica Salerno, Francesco Sessa, Renato Bernardini, Anna Valenzano, Gabriella Marsala, Christian Zammit, Roberto Avola, Marco Carotenuto, Giovanni Messina, Antonietta Messina
It is becoming increasingly apparent the importance of the central nervous system (CNS) as the major contributor to the regulation of systemic metabolism. Antipsychotic drugs are used often to treat several psychiatric disorders, including schizophrenia and bipolar disorder However, antipsychotic drugs prescription, particularly the second-generation ones (SGAs), such as clozapine and olanzapine, is related to a considerable weight gain which usually leads to obesity. The aim of this paper is to assess the influence of orexin A on sympathetic and hyperthermic reactions to several neuroleptic drugs...
January 6, 2018: Molecular Neurobiology
https://www.readbyqxmd.com/read/29297696/second-generation-antipsychotics-in-adolescent-psychiatric-patients-metabolic-effects-and-impact-of-an-early-weight-change-to-predict-longer-term-weight-gain
#6
Frederik Vandenberghe, Alexandra Najar-Giroud, Laurent Holzer, Philippe Conus, Chin B Eap, Anne-Emmanuelle Ambresin
OBJECTIVES: To examine the metabolic profile of adolescents at baseline and to determine the potential predictive power of a 1-month weight gain (WG) on weight changes during longer term second-generation antipsychotic (SGA) treatment. METHODS: A retrospective chart review study, including patients between 13 and 18 years of age and treated with SGA, was conducted. Available data at baseline, 1, 3, and 12 months of treatment were recorded. RESULTS: Four hundred fifty-six patients were included, with a median age of 15 years...
January 3, 2018: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/29284819/olanzapine-induced-psoriasis
#7
Ashish Hanmantrao Chepure, Apurva Karmveer Ungratwar
Olanzapine is a second-generation antipsychotic drug mainly used in the treatment of schizophrenia. It has several side effects including weight gain, hypercholesterolemia, and hyperglycemia, but dermatological side effects are rarely reported. We report a rare case of olanzapine-induced psoriasis.
November 2017: Indian Journal of Psychological Medicine
https://www.readbyqxmd.com/read/29220825/effects-of-nutritional-education-on-weight-change-and-metabolic-abnormalities-among-patients-with-schizophrenia-in-japan-a-randomized-controlled-trial
#8
Norio Sugawara, Toyoaki Sagae, Norio Yasui-Furukori, Manabu Yamazaki, Kazutaka Shimoda, Takao Mori, Takuro Sugai, Hiroshi Matsuda, Yutaro Suzuki, Yuji Ozeki, Kurefu Okamoto, Toshiyuki Someya
OBJECTIVE: Patients with schizophrenia have a higher prevalence of metabolic syndrome (MetS) than the general population. Minimizing weight gain and metabolic abnormalities in a population with an already high prevalence of obesity is of clinical and social importance. This randomized controlled trial investigated the effect of monthly nutritional education on weight change and metabolic abnormalities among patients with schizophrenia in Japan. METHODS: From July 2014 to December 2014, we recruited 265 obese patients who had a DSM-IV diagnosis of schizophrenia or schizoaffective disorder...
December 4, 2017: Journal of Psychiatric Research
https://www.readbyqxmd.com/read/29205757/enhancing-metabolic-monitoring-for-children-and-adolescents-using-second-generation-antipsychotics
#9
Mary Coughlin, Catherine L Goldie, Deborah Tregunno, Joan Tranmer, Marina Kanellos-Sutton, Sarosh Khalid-Khan
The prevalence of children and adolescents using second-generation antipsychotics (SGAs) has increased significantly in recent years. In this population, SGAs are used to treat mood and behavioural disorders although considered 'off-label' or not approved for these indications. Metabolic monitoring is the systematic physical health assessment of antipsychotic users utilized to detect cardiovascular and endocrine side effects and prevent adverse events such as weight gain, hyperglycaemia, hyperlipidemia, and arrhythmias...
December 4, 2017: International Journal of Mental Health Nursing
https://www.readbyqxmd.com/read/29200857/reversal-of-olanzapine-induced-weight-gain-in-a-patient-with-schizophrenia-by-switching-to-asenapine-a-case-report
#10
Kosuke Okazaki, Kazuhiko Yamamuro, Toshifumi Kishimoto
Aims: Antipsychotics are effective for treating schizophrenia, but atypical antipsychotics can cause several adverse side effects including weight gain, hyperprolactinemia, and extrapyramidal symptoms. Moreover, weight gain increases the risk of metabolic diseases. Methods: We treated a case of olanzapine-induced weight gain in a 41-year-old man with schizophrenia by switching his medication from olanzapine to asenapine. Results: The weight gain improved after switching the medication, from 80...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/29200570/clozapine-induced-acute-hypertriglyceridemia
#11
Mitesh Kumar, Ajeet Sidana
The aim of this study is to highlight the association between the use of clozapine and the early development of hypertriglyceridemia, a condition that substantially increases the risk of cardiovascular events and other medical complications. A 34-year-old female with a background history of schizophrenia presented with acute elevation of serum triglycerides and cholesterol within 2 weeks of starting clozapine. Her metabolic parameters normalized following discontinuation of clozapine. Possible hypotheses for lipid dysregulation with atypical antipsychotics include weight gain, dietary changes, and development of glucose intolerance; however, some other factors may be responsible for this rapid escalation of lipid levels...
September 2017: Indian Journal of Psychological Medicine
https://www.readbyqxmd.com/read/29188907/prescribing-patterns-in-a-psychiatrically-referred-sample-of-youth-with-autism-spectrum-disorder
#12
Julia Shekunov, Janet Wozniak, Kristina Conroy, Elizabeth Pinsky, Maura Fitzgerald, Melissa F de Leon, Abigail Belser, Joseph Biederman, Gagan Joshi
OBJECTIVE: The aim of this study was to examine the pattern of psychopharmacologic interventions in a psychiatrically referred sample of youth with autism spectrum disorder (ASD). METHODS: This retrospective chart review aimed at collecting demographic and clinical information, including data on DSM-IV-TR criteria-based psychiatric disorders and related current medication treatment and response. Data were collected in December 2011. Clinicians identified the target disorder for each medication and any adverse events...
November 28, 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/29179595/efficacy-and-safety-of-aripiprazole-lauroxil-once-monthly-versus-aripiprazole-once-monthly-long-acting-injectable-formulations-in-patients-with-acute-symptoms-of-schizophrenia-an-indirect-comparison-of-two-double-blind-placebo-controlled-studies
#13
Chris Cameron, Jacqueline Zummo, Dharmik Desai, Christine Drake, Brian Hutton, Ahmed Kotb, Peter J Weiden
BACKGROUND: Aripiprazole lauroxil (AL) is a long-acting injectable atypical antipsychotic recently approved for the treatment of schizophrenia. OBJECTIVE: To indirectly compare the safety and efficacy of AL and aripiprazole once-monthly (AOM). METHODS: We performed a systematic search to identify randomized, controlled trials of AOM and AL that met criteria for indirect comparison according to Bayesian network meta-analysis. The analysis indirectly compared AL and AOM treatment groups for efficacy by mean change in Positive and Negative Syndrome Scale (PANSS) total score and ≥30% reduction in PANSS total score, as well as tolerability including adverse events, akathisia, and weight gain...
November 27, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29175720/t4-and-waist-hip-ratio-as-biomarkers-of-antipsychotic-induced-weight-gain-in-han-chinese-inpatients-with-schizophrenia
#14
Shen Li, Ying Gao, Hao Lv, Miaomiao Zhang, Lili Wang, Rui Jiang, Chengai Xu, Xueshi Wang, Ming Gao, Yukun He, Jie Li, Wei-Dong Li
Second-generation antipsychotic agents (SGAs) cause serious metabolic side effects, including weight gain, dyslipidemia, and glucose metabolism abnormalities, which occur by unknown mechanisms. Therefore, the search for prospective markers for antipsychotic-induced weight gain (AIWG) has been of major interest. So far, predictive factors predisposing patients to the develop obesity and related metabolic disturbances induced by SGAs have been relatively less studied among large samples of Chinese schizophrenic patients...
November 21, 2017: Psychoneuroendocrinology
https://www.readbyqxmd.com/read/29170943/asenapine-treatment-in-pediatric-patients-with-bipolar-i-disorder-or-schizophrenia-a-review
#15
REVIEW
Ekaterina Stepanova, Bradley Grant, Robert L Findling
Asenapine, administered as a twice-daily (BID) sublingual tablet, is approved in the US as monotherapy for the acute treatment of manic and mixed episodes of bipolar I disorder in children and adolescents aged 10-17 years based on the positive results of one 3-week, double-blind, placebo-controlled study; the recommended dose is 2.5-10 mg BID. Although asenapine has been studied in pediatric patients with schizophrenia, it is not approved for this indication. Asenapine is not approved for pediatric use in bipolar I disorder or schizophrenia in other major markets...
November 23, 2017: Paediatric Drugs
https://www.readbyqxmd.com/read/29158012/a-randomized-double-blind-placebo-controlled-proof-of-concept-study-to-evaluate-samidorphan-in-the-prevention-of-olanzapine-induced-weight-gain-in-healthy-volunteers
#16
Bernard L Silverman, William Martin, Asli Memisoglu, Lauren DiPetrillo, Christoph U Correll, John M Kane
Antipsychotic medications are associated with weight gain and adverse metabolic effects that complicate the treatment and management of schizophrenia. Olanzapine (OLZ) in particular is associated with significant weight gain and adverse metabolic effects. The present Phase 1, proof of concept, multicenter, randomized, double-blind, placebo-controlled study investigated the safety and effect on weight of a combination of OLZ (10mg) and the opioid modulator samidorphan (SAM; 5mg) in comparison to OLZ alone in healthy, male normal weight volunteers...
November 17, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/29122637/side-effect-burden-of-antipsychotic-drugs-in-real-life-impact-of-gender-and-polypharmacy
#17
Trude Seselie Jahr Iversen, Nils Eiel Steen, Ingrid Dieset, Sigrun Hope, Ragni Mørch, Erlend Strand Gardsjord, Kjetil Nordbø Jørgensen, Ingrid Melle, Ole A Andreassen, Espen Molden, Erik G Jönsson
BACKGROUND: Antipsychotic-associated side effects are well known and represent a significant treatment challenge. Still, few large studies have investigated the overall side effect burden of antipsychotics in real-life settings. OBJECTIVE: To describe the occurrence of side effects and perceived burden of antipsychotics in a large naturalistic sample, taking polypharmacy and patient characteristics into account. METHOD: Patients (n=1087) with psychotic disorders were assessed for side effects using the Udvalg for Kliniske Undersøgelser (UKU) side effect rating scale in addition to assessment of clinical and pharmacological data...
November 6, 2017: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/29119689/decreased-5-ht2cr-and-ghsr1a-interaction-in-antipsychotic-drug-induced-obesity
#18
REVIEW
X-F Huang, K Weston-Green, Y Yu
Second generation antipsychotics (SGAs), notably atypical antipsychotics including olanzapine, clozapine and risperidone, can cause weight gain and obesity side effects. Antagonism of serotonin 2c receptors (5-HT2cR) and activation of ghrelin receptor type 1a (GHSR1a) signalling have been identified as a main cause of SGA induced obesity. Here we review the pivotal regulatory role of the 5-HT2cR in ghrelin-mediated appetite signalling. The 5-HT2cR dimerizes with GHSR1a to inhibit orexigenic signalling, while 5-HT2cR antagonism reduces dimerization and increases GHSR1a-induced food intake...
November 9, 2017: Obesity Reviews: An Official Journal of the International Association for the Study of Obesity
https://www.readbyqxmd.com/read/29116126/development-of-multivariable-models-to-predict-change-in-body-mass-index-within-a-clinical-trial-population-of-psychotic-individuals
#19
Rebecca N S Harrison, Fiona Gaughran, Robin M Murray, Sang Hyuck Lee, Jose Paya Cano, David Dempster, Charles J Curtis, Danai Dima, Hamel Patel, Simone de Jong, Gerome Breen
Many antipsychotics promote weight gain, which can lead to non-compliance and relapse of psychosis. By developing models that accurately identify individuals at greater risk of weight gain, clinicians can make informed treatment decisions and target intervention measures. We examined clinical, genetic and expression data for 284 individuals with psychosis derived from a previously published randomised controlled trial (IMPACT). These data were used to develop regression and classification models predicting change in Body Mass Index (BMI) over one year...
November 7, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29093685/bipolar-spectrum-disorders-in-male-youth-the-interplay-between-symptom-severity-inflammation-steroid-secretion-and-body-composition
#20
REVIEW
Andreas Walther, Marlene Penz, Daniela Ijacic, Timothy R Rice
The morbidity and societal burden of youth bipolar spectrum disorders (BSD) are high. These disorders are multisystemic in that adult populations there are clear interactions with inflammatory processes and steroidal physiological systems. There are much less data concerning these areas of study in youth populations with BSD. This is surprising given the association of youth-onset BSD with puberty and its associated physiological changes. In this mini-review, we overview the theoretical role of inflammatory processes and steroidal physiological systems in youth BSD, describe the greater literature in adult populations, detail the literature in youth populations when available, and overview current proposed molecular mechanistic pathways and interaction effects based on the available data...
2017: Frontiers in Psychiatry
keyword
keyword
54097
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"